Abstract:For this theme issue, we have called upon experts in the field of study of brain changes in high-risk patients with prodromal symptoms or with a first episode of schizophrenia, whether it takes place in childhood, adolescence, or adulthood. The evidence—or lack thereof—that currently exists for progressive brain changes is discussed in this theme issue by some of the leading groups in the field. The set of reviews starts with an elegant historical background on the cyclical issue of progressive brain changes in schizophrenia. The longitudinal magnetic resonance imaging studies from Edinburgh and Melbourne in prodromal subjects and subjects at increased genetic risk are then reviewed by their investigators. And finally, bringing us full circle, progressive changes after a first schizophrenia episode and in children and adolescents with early-onset psychosis are the last 2 reviews of this theme issue. Overall, the different lines of evidence suggest that some structures appear abnormal before the first sign of any symptom and therefore during a first episode, while some of these same structures and others show a higher than expected volume loss over time and thus appear different at follow-up when compared with healthy controls. These progressive changes seem to be present during the initial years after the first episode and continue even in the more chronic phase of the illness. Theresultsofthedifferentstudiesreviewedherecould be explained by separate disease processes taking place at different times in the lives of patients with schizophrenia or a single ongoing process beginning during brain development and accelerating after maximum cranial volume is reached. 1,2 Brain insults early in development, either in utero or ex utero, may affect maturational processes. In turn, earlyand latematurational processes, eg, regressive or pruning processes, result in dynamic changes in the structure of the brain well into the second and third decade of life and even later. 3 These normal processes of brain maturation, leading to decreased cortical volume, could be exaggerated in patients with schizophrenia and lead to greater than expected decreases in cortical volume and increases in sulcal cerebrospinal fluid, in the absence of neurodegeneration. Excessivebrainvolumelossoccurringmayalsobeaconsequence rather than a cause of illness, with variables such as psychosis, stress, and drug treatment playing a role in brain volume loss. 4–6 Therefore, if we attempt to integrate the findings from the studies reviewed in this issue, we would suggest that early and late neurodevelopmental abnormalities may be present in varying degrees in patients with schizophrenia. Some of these may be under genetic control, other may be the result of environmental effects. Finally, progressive changes need to be addressed, not only from the aspect of volumetric brain changes but also at the molecular, cellular, and neurochemical level, and the findings will need to be related to the influence of genetic and environmental

Altering the course of schizophrenia: progress and perspectives

Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries.

Treating Early and Treating Well: the Importance of Restoring Global Functioning for the Brains of Schizophrenia Patients

T174. Examining the Neurobiological Progression of Early Course Schizophrenia

Progressive Changes in Schizophrenia: Do They Exist and What Do They Mean?

Molecular mechanisms of schizophrenia

The Genesis of Schizophrenia: An Origin Story

What is the neurobiology of schizophrenia?

What Remains to Be Discovered in Schizophrenia Therapeutics: Contributions by Advancing the Molecular Mechanisms of Drugs for Psychosis and Schizophrenia

The Neurobiology and Treatment of First-Episode Schizophrenia

Considering schizophrenia from a prevention perspective

Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets

Transcriptional and neurochemical signatures of cerebral blood flow alterations in schizophrenia and the clinical high-risk state for psychosis

Progressive Brain Changes in Schizophrenia

The Course of Brain Abnormalities in Schizophrenia: Can We Slow the Progression?

Molecular and micro-architectural mapping of gray matter alterations in psychosis

Neuroimaging biomarkers for drug discovery and development in Schizophrenia

Toward recovery in schizophrenia: Current concepts, findings, and future research directions

Predictors of schizophrenia—a review

Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment

From Antipsychotic to Anti-Schizophrenia Drugs: Role of Animal Models